Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Pelareorep by Oncolytics Biotech for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Pelareorep is under clinical development by Oncolytics Biotech and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Pelareorep by Oncolytics Biotech for Refractory Multiple Myeloma: Likelihood of Approval
Pelareorep is under clinical development by Oncolytics Biotech and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData,...
Pelareorep by Oncolytics Biotech for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Pelareorep is under clinical development by Oncolytics Biotech and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...